BPMC
Blueprint Medicines Corp
$93.87
Earnings Summary
Revenue | $128.18Mn |
Net Profits | $-56.28Mn |
Net Profit Margins | -43.9% |
Highlights
Blueprint Medicines Corp’s revenue jumped 126.61% since last year same period to $128.18Mn in the Q3 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated -7.22% fall in its revenue since last 3-months.
Blueprint Medicines Corp’s net profit jumped 57.91% since last year same period to $-56.28Mn in the Q3 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated -12.57% fall in its net profits since last 3-months.
Blueprint Medicines Corp’s net profit margin jumped 81.43% since last year same period to -43.9% in the Q3 2024. On a quarterly growth basis, Blueprint Medicines Corp has generated -21.32% fall in its net profit margins since last 3-months.
Earnings per share (EPS) Estimates
Earnings per share (EPS) estimates of the Blueprint Medicines Corp post its latest quarter earnings
EPS Estimate Current Year | -1.66 |
Highlights
Blueprint Medicines Corp’s earning per share (EPS) estimates for the current year stand at -1.66.
Key Ratios
Key ratios of the Blueprint Medicines Corp post its Q3 2024 earnings
Earning Per Share (EPS) | -0.89 |
Highlights
Blueprint Medicines Corp’s earning per share (EPS) jumped 59.55% since last year same period to -0.89 in the Q3 2024. This indicates that the Blueprint Medicines Corp has generated 59.55% annual rate of jump in its earning per share (EPS) in the last 4 quarters.
Earnings Calendar
| Earnings Date | Estimated EPS | Reported EPS | Surprise % |
|---|---|---|---|
2024-10-30 | -0.97 | -0.89 | 8.25% |
2024-05-02 | -1.66 | 1.4 | 184.34% |
2024-08-01 | -1.29 | -0.8 | 37.98% |
₹0 US Stocks a/c Opening Fee